Completed PHASE3 INTERVENTIONAL 1-arm NCT00473434

An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia

Sponsor: Janssen-Cilag Pty Ltd

Updated 5 times since 2017 Last updated: Dec 4, 2012 Started: Apr 30, 2007 Primary completion: Aug 31, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Janssen-Cilag Pty Ltd and has accumulated 5 data snapshots since 2007. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen-Cilag Pty Ltd

Data source: Janssen-Cilag Pty Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.